-
Research Progress on the Target GDF15 Signaling Pathway and Related Drugs
Xiaonisha
July 25, 2025
Growth differentiation factor 15 (GDF15), identified and discovered from activated macrophage lineage clones, functions as an autocrine regulatory molecule in macrophages and serves as an endocrine hormone.
-
Molecular Stethoscope Announces Publication of its NAFLD/NASH Study in the American Journal of Physiology - Gastrointestinal and Liver Physiology
prnasia
February 23, 2021
Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of its human proof-of-concept study describing the stratification of NAFLD/NASH patients with clinically relevant and advanced liver fibrosis using the ...
-
Zydus gets DCGI approval for Saroglitazar Mg to treat non-alcoholic fatty liver disease
expresspharma
December 31, 2020
Saroglitazar Mg is already approved for the treatment of type-2 diabetes and NASH.
-
‘Concerning’ levels of non-alcoholic fatty liver disease among young people
pharmatimes
April 16, 2019
A new study has shown an alarmingly high prevalence of non-alcoholic fatty liver disease (NAFLD) amongst……
-
ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101
americanpharmaceuticalreview
January 11, 2019
ChemomAb announced dosing of the first patient in a Phase 1b repeated dose clinical trial with CM-101 in non-alcoholic fatty liver disease (NAFLD) patients....
-
BASF launches first dedicated product to help patients with NAFLD in the US
cphi-online
February 26, 2018
BASF's Hepaxa is the first product in the US specifically designed to address a buildup of fat in the liver in NAFLD patients.
-
Boehringer Ingelheim Initiates Phase IIa Study of Compound Acquired from Pharmaxis
americanpharmaceuticalreview
August 25, 2017
Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
